Critical care perspective on immunotherapy in lung transplantation

Journal of Intensive Care Medicine

Volumn 21, Issue 6, 2006, Pages 327-344

  Taylor, Jennifer L ^a   Palmer, Scott M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Complications; Immunosuppressive agents; Intensive care; Lung transplant

Indexed keywords

ALLOPURINOL; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; BASILIXIMAB; CALCINEURIN INHIBITOR; CEFTAZIDIME; CIMETIDINE; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MIFEPRISTONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PHENYTOIN; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; SANCYA; STEROID; TACROLIMUS; TEMSIROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANAPHYLAXIS; ANTIBIOTIC PROPHYLAXIS; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; BRONCHOSPASM; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CONFUSION; CYTOKINE RELEASE; DRUG MECHANISM; DRUG MEGADOSE; EDEMA; FEVER; FLUID RETENTION; GRAFT RECIPIENT; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTENSIVE CARE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG EDEMA; LUNG GRAFT REJECTION; LUNG TOXICITY; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MENINGITIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEIZURE; SEPSIS; SERUM SICKNESS; SIDE EFFECT; STOMACH ULCER; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOXIC EPIDERMAL NECROLYSIS; TREMOR; VOMITING; WOUND HEALING IMPAIRMENT;

ANIMALS; BACTERIAL INFECTIONS; BRAIN DISEASES; CRITICAL CARE; CROSS INFECTION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LUNG DISEASES, FUNGAL; LUNG DISEASES, INTERSTITIAL; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MULTIVARIATE ANALYSIS; MYCOSES; POSTOPERATIVE COMPLICATIONS; RADIOGRAPHY, THORACIC; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; SERUM SICKNESS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33750510468     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066606292876     Document Type: Review

References (170)

1. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report - 2005. J Heart Lung Transplant. 2005;24:956-967.
2. de Perrot M, Chaparro C, McRae K, et al. Twenty-year experience of lung transplantation at a single center: influence of recipient diagnosis on long-term survival. J Thorac Cardiovasc Surg. 2004;127:1493-1501.
3. Kruger RM, Shannon WD, Arens MO, et al. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation. 1999;68:1272-1279.
4. Hadjiliadis D, Chaparro C, Reinsmoen NL, et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant. 2005;24(7 suppl):S249-S2454.
5. Hardy JD, Dalton ML Jr, Walker GR Jr. Lung homontransplantation in man. JAMA. 1963;186:1065-1074.
6. Unilateral lung transplantation for pulmonary fibrosis. Toronto Lung Transplant Group. N Engl J Med. 1986;314:1140-1145.
7. Cooper JD, Pearson FG, Patterson GA, et al. Technique of successful lung transplantation in humans. J Thorac Cardiovasc Surg. 1987;93:173-181.
8. Magee CC, Denton MD, Milford EL. Immunosuppressive agents in organ transplantation. Hosp Med. 1999;60:364-369.
9. Opelz G. Multicenter evaluation of immunosuppressive regimens in heart transplantation. The Collaborative Transplant Study. Transplant Proc. 1997;29:617-619.
10. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med. 1982;306:557-564.
11. Kriett JM, Smith CM, Hayden AM, et al. Lung transplantation without the use of antilymphocyte antibody preparations. J Heart Lung Transplant. 1993;12:915-922.
12. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J. 2004;23:159-171.
13. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg. 1995;60:580-584.
14. Bando K, Paradis IL, Komatsu K, et al. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg. 1995;109:49-57.
15. Zuckermann A, Reichenspurner H, Birsan T, et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg. 2003;125:891-900.
16. Ross DJ, Waters PF, Levin M, et al., Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant. 1998;17:768-774.
17. Zuckermann A, Klepetko W, Birsan T, et al. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. J Heart Lung Transplant. 1999;18:432-440.
18. Palmer, S.M., Baz MA, Sanders L, et al., Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation, 2001;71:1772-1776.
19. Glanville AR, Corris PA, McNeil KD, et al. Mycophenolate mofetil (MMF) vs azathioprine (AZA) in lung transplantation for the prevention of bronchiolitis obliterans syndrome (BOS): results of a 3 year international randomised trial. J Heart Lung Transplant. 2003;22(1 suppl 1):S207.
20. King-Biggs MB, Dunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation. 2003;75:1437-1443.
21. Shitrit D, Yussim A, Kramer MR. Role of siroliumus, a novel immunosuppressive drug in heart and lung transplantation. Respir Med. 2004;98:892-897.
22. Wain JC, Wright CD, Ryan DP, et al. Induction immunosuppression for lung transplantation with OKT3. Ann Thorac Surg. 1999;67:187-193.
23. Palmer SM, Miralles AP, Lawrence CM, et al. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest. 1999;116:127-133.
24. Gerbase MW, de Perrot M, Spiliopoulas M, Nicod LP. Selective monoclonal versus polyclonal antibodies for induction of immunosuppression in lung recipients. Clin Pharmacol Ther. 2002;72:103.
25. Brock MV, Borja MC, Ferber L, et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant. 2001;20:1282-1290.
26. McCurry KR, Iacono A, Zeevi A, et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by post-transplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg. 2005;130:528-537.
27. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770-781.
28. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: eighteenth official report - 2001. J Heart Lung Transplant. 2001;20:805-815.
29. Lyon GM, McKim DA, Shennib H, Dales RE. Mycoplasma hominis pneumonia complicating bilateral lung transplantation: case report and review of the literature. Chest. 1997;112:1428-1432.
30. Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med. 1999;160:1611-1616.
31. Chaparro C, Kesten S. Infections in lung transplant recipients. Clin Chest Med. 1997;18:339-351.
32. Chan KM, Allen SA. Infectious pulmonary complications in lung transplant recipients. Semin Respir Infect. 2002;17:291-302.
33. Trzeciak S, Sharer R, Piper D, et al. Infections and severe sepsis in solid-organ transplant patients admitted from a university-based ED. Am J Emerg Med. 2004;22:530-533.
34. Palmer SM, Alexander BD, Sanders LL, et al. Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients. Transplantation. 2000;69:2360-2366.
35. Danziger-Isakov LA, Sweet S, Delamorena M, et al. Epidemiology of bloodstream infections in the first year after pediatric lung transplantation. Pediatr Infect Dis J. 2005;24:324-330.
36. De Soyza A, Archer L, Wardle J, et al. Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis. J Heart Lung Transplant. 2003;22:764-769.
37. Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med. 2001;163:43-48.
38. Aris RM, Routh JC, LiPuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med. 2001;164:2102-2106.
39. Paradis IL, Williams P. Infection after lung transplantation. Semin Respir Infect. 1993;8:207-215.
40. Orens JB. Cytomegalovirus prophylaxis with IV ganciclovir in lung transplant recipients: the long and the short of it! Chest. 1999;116:1152-1153.
41. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002;21:271-281.
42. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis. 1993;147:1017-1023.
43. Zamora MR. Controversies in lung transplantation: management of cytomegalovirus infections. J Heart Lung Transplant. 2002;21:841-849.
44. Soghikian MV, Valentine VG, Berry GJ, et al. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant. 1996;15:881-887.
45. Barber L, Egan JJ, Lomax J, et al. A prospective study of a quantitative PCR ELISA assay for the diagnosis of CMV pneumonia in lung and heart-transplant recipients. J Heart Lung Transplant. 2000;19:771-780.
46. Bhorade SM, Sandesara C, Garrity ER, et al. Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients. J Heart Lung Transplant. 2001;20:928-934.
47. Holt ND, Gould FK, Taylor CE, et al. Incidence and significance of noncytomegalovirus viral respiratory infection after adult lung transplantation. J Heart Lung Transplant. 1997;16:416-419.
48. Smyth RL, Higenbottam TW, Scott JP, et al. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation. 1990;49:735-739.
49. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis. 2001;3:128-137.
50. Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis. 2002;4(suppl 3):24-31.
51. Mehrad B, Paciocco G, Martinez FJ, et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest. 2001;119:169-175.
52. Dummer JS, Lazariashvilli N, Barnes J, et al. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant. 2004;23:1376-1381.
53. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation. 2001;72:545-548.
54. Drew RH, Dodds Ashley D, Benjamin DK, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation. 2004;77:232-237.
55. Hamacher J, Spiliopoulos A, Kurt AM, Nicod LP. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur Respir J. 1999;13:180-186.
56. Husain S, McCurry K, Dauber J, et al. Nocardia infection in lung transplant recipients. J Heart Lung Transplant. 2002;21:354-359.
57. Chakinala MM, Walter MJ. Community acquired respiratory viral infections after lung transplantation: clinical features and long-term consequences. Semin Thorac Cardiovasc Surg. 2004;16:342-349.
58. Flynn JD, Akers WS, Jones M, et al. Treatment of respiratory syncytial virus pneumonia in a lung transplant recipient: case report and review of the literature. Pharmacotherapy. 2004;24:932-938.
59. McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22:745-753.
60. Vilchez RA, Dauber J, McCurry K, et al. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant. 2003;3:116-120.
61. Palmer SM Jr, Henshaw NG, Howell DN, et al. Community respiratory viral infection in adult lung transplant recipients. Chest. 1998;113:944-950.
62. Trulock EP, Bolman RM, Genton R. Pulmonary disease caused by Mycobacterium chelonae in a heart-lung transplant recipient with obliterative bronchiolitis. Am Rev Respir Dis. 1989;140:802-805.
63. Fairhurst RM, Kubak BM, Shpiner RB, et al. Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung Transplant. 2002;21:391-394.
64. Baisi A, Nosotti M, Chella B, et al. Relapsing cutaneous Mycobacterium chelonae infection in a lung transplant patient. Transpl Int. 2005;18:1117-1119.
65. Winthrop KL, Kubak BM, Peques DA, et al. Transmission of mycobacterium tuberculosis via lung transplantation. Am J Transplant. 2004;4:1529-1533.
66. Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. Chest. 1999;115:741-745.
67. Bravo C, Roldan J, Roman A, et al. Tuberculosis in lung transplant recipients. Transplantation. 2005;79:59-64.
68. Lau CL, Patterson GA, Palmer SM. Critical care aspects of lung transplantation. J Intensive Care Med. 2004;19:83-104.
69. Roberts SA, Franklin JC, Mijch A, et al. Nocardia infection in heart-lung transplant recipients at Alfred Hospital, Melbourne, Australia, 1989-1998. Clin Infect Dis. 2000;31:968-972.
70. Chan CC, Abi-Saleh WJ, Arroliga AC, et al. Diagnostic yield and therapeutic impact of flexible bronchoscopy in lung transplant recipients. J Heart Lung Transplant. 1996;15:196-205.
71. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931-940.
72. Rocha PN, Rocha AT, Palmer SM, et al. Acute renal failure after lung transplantation: incidence, predictors and impact on perioperative morbidity and mortality. Am J Transplant. 2005;5:1469-1476.
73. Greenberg A, Egel JW, Thompson ME, et al. Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. Am J Kidney Dis. 1987;9:12-22.
74. Puschett JB, Greenberg A, Holley J, McCauley J. The spectrum of ciclosporin nephrotoxicity. Am J Nephrol. 1990;10:296-309.
75. Zaltzman JS, Pei Y, Maurer J, et al. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation. 1992;54:875-878.
76. Ishani A, Erturk S, Hertz MI, et al. Predictors of renal function following lung or heart-lung transplantation. Kidney Int. 2002;61:2228-2234.
77. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589-600.
78. Terrell DR, Williams LA, Vesely SK, et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3:1432-1436.
79. George JN. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clin Acta Hematol Oncol. 2005;3:627-632.
80. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood. 2005;106:11-17.
81. Schmidt RJ, Venkat KK, Dumler F. Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. Transplant Proc. 1991;23:3156-3157.
82. Singh N, Gayowski T, Marino IR. Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int. 1996;9:68-75.
83. Mihatsch MJ, Kyo M, Morozumi K, et al. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol. 1998;49:356-363.
84. Butkus DE, Herrera GA, Raju SS. Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation. Transplantation. 1992;54:159-162.
85. Abraham KA, Little MA, Dorman AM, et al. Hemolytic-uremic syndrome in association -with both cyclosporine and tacrolimus. Transpl Int. 2000;13:443-447.
86. Reid DW, Street A, Mansfield D, et al. Microangiopathic haemolytic anaemia and thrombocytopenia following lung volume reduction surgery in a single lung transplant recipient on maintenance tacrolimus (FK506) therapy. Respirology 2003;8:243-245.
87. Shitrit D, Starobin D, Aravot D, et al. Tacrolimus-induced hemolytic uremic syndrome case presentation in a lung transplant recipient. Transplant Proc. 2003;35:627-628.
88. Abramowicz D, Pradier O, Marchant A, et al. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet. 1992;339:777-778.
89. Pradier O, Marchant A, Abramowicz D, et al. Procoagulant effect of the OKT3 monoclonal antibody: involvement of tumor necrosis factor. Kidney Int. 1992;42:1124-1129.
90. Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis. 1998;177:48-56.
91. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore). 1997;76:369-380.
92. Grace AA, Barradas MA, Mikhailidis DP, et al. Cyclosporine A enhances platelet aggregation. Kidney Int. 1987;32:889-895.
93. Dzik WH, Georgi BA, Khettry U, Jenkins RL, et al. Cyclosporine-associated thrombotic thrombocytopenic purpura following liver transplantation - successful treatment with plasma exchange. Transplantation. 1987;44:570-572.
94. Trimarchi HM, Truong DL, Brennan S, et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation. 1999;67:539-544.
95. Bren A, Pajek J, Grego K, et al. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy. Transplant Proc. 2005;37:1889-1891.
96. Guella A, Daoud M, Al Dayel A. Uneventful re-treatment with cyclosporin in two cases of cyclosporin-induced haemolytic uraemic syndrome. Nephrol Dial Transplant. 1998;13:1864-1865.
97. Kaufman DB, Kaplan B, Kanwar S, et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. Transplantation. 1995;59:1737-1739.
98. Abdalla AH, al-Sulaiman MH, al-Khader AA. FK 506 as an alternative in cyclosporin-induced hemolytic uremic syndrome in a kidney transplant recipient. Transpl Int. 1994;7:382-384.
99. Myers JN, Shabshab SF, Burton NA, et al. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome. J Heart Lung Transplant. 1999;18:1024-1026.
100. Bell WR, Braine HG, Ness PM, et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325:398-403.
101. Sens YA, Miorin LA, Silva HG, et al. Acute renal failure due to hemolytic uremic syndrome in adult patients. Ren Fail. 1997;19:279-282.
102. Au WY, Lie AK, Lam CC, et al. Tacrolimus (FK 506) induced thrombotic thrombocytopenic purpura after ABO mis-matched second liver transplantation: salvage with plasmapheresis and prostacyclin. Haematologica. 2000;85:659-662.
103. Lin CC, King KL, Chao YW, et al. Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol. 2003;16:580-585.
104. Mach-Pascual S, Samii K, Beris P. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. Am J Hematol. 1996;52:310-312.
105. Walder B, Ricou B, Suter PM. Tacrolimus (FK 506)-induced hemolytic uremic syndrome after heart transplantation. J Heart Lung Transplant. 1998;17:1004-1006.
106. Hochstetler LA, Flanigan MJ, Lager DJ. Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy. Am J Kidney Dis. 1994;23:444-450.
107. Gatti S, Arru M, Reggiani P, et al. Successful treatment of hemolytic uremic syndrome after liver-kidney transplantation. J Nephrol. 2003;16:586-590.
108. Banerjee D, Kupin W, Roth D. Hemolytic uremic syndrome after multivisceral transplantation treated with intravenous immunoglobulin. J Nephrol. 2003;16:733-735.
109. Yassa SK, Blessios G, Marinides G, Venuto RC. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome. Clin Transplant. 2005;19:423-426.
110. Dillman RO, Beauregard JC, Halpern SE, Clutter M. Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies. J Biol Response Mod. 1986;5:73-84.
111. Leonard PA, Woodside KJ, Gugliuzza KK, et al. Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. Transplantation. 2002;74:1697-1700.
112. Baudouin V, Crusiaux A, Haddad D, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation. 2003;76:459-463.
113. Barros VR, Rocha V, Garcia VD, Garcia CD. Anaphylactic shock after retreatment with basiliximab. Transplant Proc. 2003;35:579.
114. Pharand C, Palisaitis DA, Hamel D. Potential anaphylactic shock with abciximab readministration. Pharmacotherapy. 2002;22:380-383.
115. Guzzo JA, Nichols TC. Possible anaphylactic reaction to abciximab. Catheter Cardiovasc Interv. 1999;48:71-73.
116. Stallmach A, Giese T, Schmidt C, et al. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol. 2004;16:627-630.
117. Puchner TC, Kugathasan S, Kelly KG, et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis. 2001;7:34-37.
118. Abramowicz D, Crusiaux A, Goldman M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med. 1992;327:736.
119. Werier J, Cheung AH, Matas AJ. Anaphylactic hypersensitivity reaction after repeat OKT3 treatment. Lancet. 1991;337:1351.
120. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation. 1989;47:606-608.
121. Raasveld MH, Bemelman FJ, Schellekens PT, et al. Complement activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney Int. 1993;43:1140-1149.
122. Chin C, Pittson S, Luikart H, et al. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation. 2005;80:477-481.
123. Jeyarajah DR, Thistlethwaite JR Jr. General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc. 1993;25(suppl 1):16-20.
124. Boggi U, Danesi R, Vistoli F, et al. A benefit-risk assessment of basiliximab in renal transplantation. Drug Saf. 2004;27:91-106.
125. Swiatecka-Urban A. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. Paediatr Drugs. 2003;5:699-716.
126. Prin Mathieu C, Renoult E, Kennel De March A, et al. Serum anti-rabbit and anti-horse IgG, IgA, and IgM in kidney transplant recipients. Nephrol Dial Transplant. 1997;12:2133-2139.
127. Tanriover B, Chuang P, Fishbach B, et al. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation. 2005;80:279-281.
128. Penn I. Cancers complicating organ transplantation. N Engl J Med. 1990;323:1767-1769.
129. Tanner JE, Alfieri C. The Epstein-Barr virus and posttransplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis. 2001;3:60-69.
130. Andreone P, Gramenzi A, Lorenzini S, et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med. 2003;163:1997-2004.
131. Boyle GJ, Michaels MG, Webber SA, et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr. 1997;131:309-313.
132. Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995;86:3333-3340.
133. Ellis D, Jaffe R, Green M, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation. 1999;68:997-1003.
134. Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation. 2000;70:94-99.
135. Sokal EM, Antunes H, Bequin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation. 1997;64:1438-1442.
136. Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979;2:1033-1036.
137. Penn I. Cancers following cyclosporine therapy. Transplantation. 1987;43:2-35.
138. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1:583-587.
139. Pirsch JD. Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. Transplantation. 1999;68:1203-1205.
140. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222-230.
141. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003;76:1289-1293.
142. Guthery SL, Heubi G, Bucuvalas JC, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation. 2003;75:987-993.
143. Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 1999;68:1851-1854.
144. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97:1165-1171.
145. Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation. 2001;72:1012-1019.
146. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71:1076-1088.
147. Reams BD, McAdams HP, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest. 2003;124:1242-1249.
148. Koffman BH, Kennedy AS, Heyman M, et al. Use of radiation therapy in posttransplant lymphoproliferative disorder (PTLD) after liver transplantation. Int J Cancer. 2000;90:104-109.
149. Davis CL, Wood BL, Sabath DE, et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation. 1998;66:1770-1779.
150. Niedermeyer J, Hoffmeyer F, Hertenstein B, et al. Treatment of lympho-proliferative disease with rituximab. Lancet. 2000;355:499.
151. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000;11(suppl 1):113-116.
152. Verschuuren EA, Stevens SJ, van Imhoff GW, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation. 2002;73:100-104.
153. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999;353:1083-1091.
154. West ML. Bronchiolitis Obliterans and organizing pneumonia in renal transplant recipients. Transplantation. 2000;69:1531.
155. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med. 2000;343:225-226.
156. Singer SJ, Tiernan R, Sullivan EJ. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med. 2000;343:1815-1816.
157. McWilliams TJ, Levvey BJ, Russell PA, et al. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant. 2003;22:210-213.
158. Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation. 2004;77:1215-1220.
159. Lindenfeld JA, Simon SF, Zamora MR, et al. BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus. Am J Transplant. 2005;5:1392-1396.
160. Manito N, Kaplinsky EJ, Bernat R, et al. Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient. J Heart Lung Transplant. 2004;23:780-782.
161. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494-500.
162. Singh N, Bonham A, Fukui M. Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. Transplantation. 2000;69:467-472.
163. Miller LW. Cyclosporine-associated neurotoxicity. The need for a better guide for immunosuppressive therapy. Circulation. 1996;94:1209-1211.
164. Zheng W. Neurotoxicology of the brain barrier system: new implications. J Toxicol Clin Toxicol. 2001;39:711-719.
165. de Groen PC, Wiesner RH, Krom RA. Advanced liver failure predisposes to cyclosporine-induced central nervous system symptoms after liver transplantation. Transplant Proc. 1989;21:2456.
166. Schwartz RB, Bravo SM, Klufas RA, et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol. 1995;165:627-631.
167. Chang SH, Lim CS, Low TS, et al. Cyclosporine-associated encephalopathy: a case report and literature review. Transplant Proc. 2001;33:3700-3701.
168. Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology. 1995;45:1962-1964.
169. Casanova B, Prieto M, Deya E, et al. Persistent cortical blindness after cyclosporine leukoencephalopathy. Liver Transpl Surg. 1997;3:638-640.
170. Nishie M, Kurahashi K, Ogawa M, et al. Posterior encephalopathy subsequent to cyclosporin A presenting as irreversible abulia. Intern Med. 2003;42:750-755.